Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681305 | 1.00 | FOLH1 (0.58) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL20530 | 0.85 | FOLH1 (0.62) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL20529 | 0.85 | FOLH1 (0.62) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL919220 | 0.85 | FOLH1 (0.62) | FOLH1CA1CA2SLC6A5GSR | |
| Hydrochloric Acid SCHEMBL15669796 | 0.84 | FOLH1 (0.60) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL31390430 | 0.84 | FOLH1 (0.60) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL1387574 | 0.84 | FOLH1 (0.60) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL31621379 | 0.84 | FOLH1 (0.60) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL16238796 | 0.84 | FOLH1 (0.60) | FOLH1CA1CA2SLC6A5GSR | |
| SCHEMBL31621381 | 0.84 | FOLH1 (0.60) | FOLH1CA1CA2SLC6A5GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287653-A1 | METHOD FOR PRODUCING INHIBITORS AND INHIBITORS FORMED THEREFROM | THE UNIVERSITY OF AKRON (US) | 2008-11-20 | — | — | US | claimed |
| US-20080286815-A1 | SPECTROPHOTOMETRIC ASSAY FOR HUMAN HISTONE DEACETYLASE 8 | THE UNIVERSITY OF AKRON (US) | 2008-11-20 | — | — | US | claimed |
| EP-3956026-B9 | P16INK4A INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | UNIV SORBONNE (FR) | 2023-10-04 | — | — | EP | disclosed |
| EP-3956026-B1 | P16INK4A INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | UNIV SORBONNE (FR) | 2023-06-07 | — | — | EP | disclosed |
| US-20220251564-A1 | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | SORBONNE UNIVERSITE (FR) | 2022-08-11 | — | — | US | disclosed |
| CN-114096313-A | P16 for use in the prevention or treatment of Huntington's diseaseINK4aInhibitors | 索邦大学 | 2022-02-25 | — | — | CN | disclosed |
| EP-3956026-A1 | P16INK4A INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | SORBONNE UNIVERSITE (FR) | 2022-02-23 | — | — | EP | disclosed |
| CN-110143900-B | Methods of treatment using SIRT2 modulators | 康奈尔大学 | 2021-08-03 | — | — | CN | disclosed |
| WO-2020212597-A1 | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | SORBONNE UNIVERSITE (FR) | 2020-10-22 | — | — | WO | disclosed |
| EP-2647720-B1 | PEPTIDE LIBRARY PRODUCTION METHOD, PEPTIDE LIBRARY, AND SCREENING METHOD | UNIV TOKYO (JP) | 2019-06-19 | — | — | EP | disclosed |
| CN-105037278-B | Sirt5 regulator and its screening technique | 康奈尔大学 | 2019-05-03 | — | — | CN | disclosed |
| EP-2596122-A2 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME | Cornell University (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013052727-A1 | METHODS OF TREATMENT USING MODULATORS OF SIRT2 | CORNELL UNIVERSITY (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130065248-A1 | REAGENTS AND METHODS FOR SIRTUIN CAPTURE | CORNELL UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2012006391-A2 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME | CORNELL UNIVERSITY (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011146636-A2 | REAGENTS AND METHODS FOR SIRTUIN CAPTURE | CORNELL UNIVERSITY (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011050152-A2 | SITE-SPECIFIC MODIFICATION OF PROTEINS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20080287653-A1 | METHOD FOR PRODUCING INHIBITORS AND INHIBITORS FORMED THEREFROM | THE UNIVERSITY OF AKRON (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287653-A1 | METHOD FOR PRODUCING INHIBITORS AND INHIBITORS FORMED THEREFROM | THE UNIVERSITY OF AKRON (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080286815-A1 | SPECTROPHOTOMETRIC ASSAY FOR HUMAN HISTONE DEACETYLASE 8 | THE UNIVERSITY OF AKRON (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251564-A1 | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | HTT, CDKN1A, TP53 | FOLH1 3867/4885CA1 4179/4885CA2 4566/4885 |
| US-20130065248-A1 | REAGENTS AND METHODS FOR SIRTUIN CAPTURE | SIRT3, SIRT1, SIRT2 | FOLH1 1097/4885CA1 2867/4885CA2 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.